Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Orexo AB    ORX   SE0000736415

Delayed Quote. Delayed  - 07/29 05:29:35 pm
52 SEK   +2.97%
07/12 OREXO : Interim Report January-June 2016
07/09 OREXO : welcomes increased access to treatment for patients with opi..
07/07 OREXO : welcomes increased access to treatment for patients with opi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Orexo : Interim report January-March 2014

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2014 | 08:14am CEST

Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013.

Zubsolv®, now with broader market access

First quarter 2014

  • Total net revenues amounted to MSEK 101.9 (139.8). Revenues from launched products, excluding one-off milestone, amounted to MSEK 101.9 (72.1).
  • Earnings after tax were MSEK -21.1 (27.5).
  • Earnings per share were SEK -0.66 (0.95).
  • Cash flow from operating activities amounted to MSEK -99.7 (-5.0).
  • Cash and cash equivalents amounted to MSEK30.7 (218.9) before non-utilized credit facilities of MSEK 105.
  • Reimbursement agreement for Zubsolv signed with UnitedHealth Group and OptumRx.

After the period

  • Orexo has engaged Pareto Securities to investigate the market regarding issuance of a corporate bond. Proceeds would be used to finance the continued development and commercialization of Zubsolv and to reduce the existing bank debt.
MSEK 2014 2013 2013
Jan-Mar Jan-Mar Jan-Dec
Net revenues 101.9 139.8 429.4
Revenues from launched products 101.9 136.4 421.6
EBIT -16.2 30.2 -139.7
EBITDA -13.7 31.5 -89.1
Earnings after tax -21.1 27.5 -154.9
Earnings per share, SEK -0.66 0.95 -5.16
Cash flow from operating activities -99.7 -5.0 -265.8
Cash and cash equivalents 30.7 218.9 105.6


Teleconference
CEO Nikolaj Sørensen and CFO Henrik Juuel will present the report at a teleconference today on two occasions:
9:00am CET
Telephone: SE: +46 8 519 993 61, UK: +44 20 319 405 54 or US: +1 855 269 26 07
http://financialhearings.nu/140425/orexo-eu/

2:00pm CET
Telephone: SE: +46 8 519 993 55, UK: +44 20 319 405 50 or US: +1 855 269 26 07
http://financialhearings.nu/140425/orexo-us/

For further information, please contact:
Nikolaj Sørensen, CEO or Henrik Juuel, EVP and CFO
Tel: +46 (0)18 780 88 00, E-mail: ir@orexo.com

CEO's comments
During the quarter, Orexo's focus has been to continue to improve the reimbursement status of Zubsolv. I am pleased to see that our dedication and efforts continue to pay off, with the announcement of an exclusive agreement with the largest insurance company in the USA, UnitedHealth Group. This agreement makes Zubsolv the only buprenorphine/naloxone product available to patients within UnitedHealth Group's highly controlled plans.

During the quarter, sales of Zubsolv doubled compared to the end of 2013, as a result of the brand exclusivity agreement with CVS Caremark and Medimpact. With this improved reimbursement, level we restricted the terms of the patient support program in order to increase the profitability of each prescription. As a result, the number of tablets per script nearly doubled within a few weeks, which temporarily slowed the growth of prescriptions week on week, but had a very positive impact on sales.

Improving reimbursement is currently the single most important commercial initiative to reach more patients. Zubsolv is clearly benefiting from being reimbursed in parity with or better than our competitors and we continue to work intensively to improve this position further. In addition to UnitedHealth Group, we have during the period either signed agreements or secured reimbursement improvements with several regional plans where Zubsolv has not previously been reimbursed. For example these plans cover patients located in the metro-Philadelphia area, Pittsburgh vicinity and across Ohio. The regional plans are, on a nationwide scale, smaller but they are critical to gain market leadership in high value concentrated U.S. geographies. The improvement of regional coverage will continue during the second quarter and I expect that this will start to have an effect on sales from late in the second quarter, in parallel with the agreement with UnitedHealth Group.

As a result of what we have learned during the initial launch period, the sales force has been restructured during the first quarter. We have increased the number of representatives in some areas with good market access, and replaced a part of the sales force with representatives having a higher competency and experience profile relative to the addiction specialty field. This restructuring has led to a typical disruption in sales force performance, but we have also experienced territories where sales representatives with a consistent visit frequency and selling approach in their calls clearly are achieving better results. Therefore, we are monitoring and working closely with our partner Publicis Touchpoint Solutions to improve the sales force performance and ability to impact prescriptions.

We continue to work hard to strengthen the differentiation of Zubsolv, and the three new clinical studies ongoing are expected to improve our dialogue with prescribers and increase confidence in Zubsolv and Orexo as the first results become available this summer. We are also working intensively to broaden our dosage range offerings.

Zubsolv is still in a launch mode and I expect the sales development to improve in a stepwise fashion as reimbursement improves and as the results of our clinical trials become available. We are well on track to reach our competitive reimbursement target level for Zubsolv. I am optimistic that this together with our highly dedicated US and SE organization, will enhance the conditions for strong sales growth in 2014.

Nikolaj Sørensen
President and CEO

Please note
Orexo AB publ discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Market Act. The information was provided for public release on April 25, 2014, at 8:00 a.m. This report has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall prevail.

The following files are available for download:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OREXO AB
07/12 OREXO : Interim Report January-June 2016
07/09 OREXO : welcomes increased access to treatment for patients with opioid dependen..
07/07 OREXO : welcomes increased access to treatment for patients with opioid dependen..
07/07 OREXO : welcomes increased access to treatment for patients with opioid dependen..
07/01 OREXO : signs license agreement with Mundipharma, which obtains ex-US global rig..
06/30 OREXO : Mundipharma obtains global ex-US rights to Zubsolv
06/30 OREXO : signs license agreement with Mundipharma, which obtains ex-US global rig..
06/30 OREXO : signs license agreement with Mundipharma, which obtains ex-US global rig..
06/28 OREXO : sees very limited exposure to the UK and the British pound
06/21 OREXO : Sees Very Limited Exposure to the UK and the British Pound
More news
Sector news : Pharmaceuticals - NEC
07:33pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
04:26pDJABBVIE : Results Boosted by Humira, Pipeline Growth
04:17pDJABBVIE : Results Boosted by Humira, Pipeline Growth
02:26pDJMerck Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Expanded label for ZUBSOLV cleared in U.S.
2015 CVS cuts Orexo's Zubsolv from preferred position; sales could be impacted as ..
2015 HOW TO BEAT THE HERD MENTALITY : Highline's Michael Higgins
Advertisement
Financials ( SEK)
Sales 2016 671 M
EBIT 2016 -46,3 M
Net income 2016 -71,0 M
Debt 2016 239 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 43,63
EV / Sales 2016 2,95x
EV / Sales 2017 2,28x
Capitalization 1 740 M
More Financials
Chart OREXO AB
Duration : Period :
Orexo AB Technical Analysis Chart | ORX | SE0000736415 | 4-Traders
Full-screen chart
Technical analysis trends OREXO AB
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 68,5  SEK
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nikolaj Sørensen President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Executive Chairman
Jesper Lind Chief Operating Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Peter Edman Chief Scientific Officer & Head-R&D
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OREXO AB-21.12%201
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results